Evidence map›Paper›PMID 28409828›Full record

ArticleJournal of cellular physiology2017

Leucine elicits myotube hypertrophy and enhances maximal contractile force in tissue engineered skeletal muscle in vitro.

Neil R W Martin, Mark C Turner, Robert Farrington, Darren J Player, Mark P Lewis

Open access · hybridAbstract read
In one paragraph

Article in Journal of cellular physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. A Pound of Flesh: What Cachexia Is and What It Is Not.Diagnostics (Basel, Switzerland) · 2021
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Neil R W MartinSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.ORCID http://orcid.org/0000-0002-1988-047X
Mark C TurnerSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
Robert FarringtonSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
Darren J PlayerSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
Mark P LewisSchool of Sport, Exercise and Health Sciences, Loughborough University, Loughborough, UK.
Loughborough University · GB

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research G0900762/1
6 · The paper itself

Abstract

The amino acid leucine is thought to be important for skeletal muscle growth by virtue of its ability to acutely activate mTORC1 and enhance muscle protein synthesis, yet little data exist regarding its impact on skeletal muscle size and its ability to produce force. We utilized a tissue engineering approach in order to test whether supplementing culture medium with leucine could enhance mTORC1 signaling, myotube growth, and muscle function. Phosphorylation of the mTORC1 target proteins 4EBP-1 and rpS6 and myotube hypertrophy appeared to occur in a dose dependent manner, with 5 and 20 mM of leucine inducing similar effects, which were greater than those seen with 1 mM. Maximal contractile force was also elevated with leucine supplementation; however, although this did not appear to be enhanced with increasing leucine doses, this effect was completely ablated by co-incubation with the mTOR inhibitor rapamycin, showing that the augmented force production in the presence of leucine was mTOR sensitive. Finally, by using electrical stimulation to induce chronic (24 hr) contraction of engineered skeletal muscle constructs, we were able to show that the effects of leucine and muscle contraction are additive, since the two stimuli had cumulative effects on maximal contractile force production. These results extend our current knowledge of the efficacy of leucine as an anabolic nutritional aid showing for the first time that leucine supplementation may augment skeletal muscle functional capacity, and furthermore validates the use of engineered skeletal muscle for highly-controlled investigations into nutritional regulation of muscle physiology.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCarrier ProteinsCell Cycle ProteinsCell LineDose-Response Relationship, DrugElectric StimulationEukaryotic Initiation FactorsHypertrophyLeucineMechanistic Target of Rapamycin Complex 1MiceMultiprotein ComplexesMuscle ContractionMuscle Fibers, SkeletalMuscle StrengthAdaptor Proteins, Signal TransducingCarrier ProteinsCell Cycle ProteinsEif4ebp1 protein, mouseEukaryotic Initiation FactorsLeucineMechanistic Target of Rapamycin Complex 1mTOR protein, mouseMultiprotein ComplexesPhosphoproteinsProtein Kinase InhibitorsRibosomal Protein S6ribosomal protein S6, mouseTOR Serine-Threonine Kinasesamino acidshypertrophymTORC1skeletal muscle

Identifiers

PMID28409828
PMCPMC5518187
OpenAlexW2607417071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.